



May 02, 2024

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Press release on unaudited Financial Results for quarter ended March 31,2024**

We are enclosing herewith the Press Release, regarding the unaudited Financial Results for quarter ended March 31,2024, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record.

Thanking you.  
Yours faithfully,

For Procter & Gamble Health Limited

**Zeal Rupani**  
Company Secretary

**Procter & Gamble Health Limited**

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,  
P&G Plaza, Cardinal Gracias Road, Chakala,  
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000  
[www.pghealthindia.com](http://www.pghealthindia.com)



## Procter & Gamble Health Announces Third Quarter Results

*Sales of ₹248 Crores and PAT of ₹46 Crores for quarter ended March 31, 2024*

**Mumbai, 2<sup>nd</sup> May, 2024:** Procter & Gamble Health Limited announced today its financial results for the quarter ended March 31, 2024. The company delivered total sales of ₹248 crores for the quarter ended March 31, 2024, vs ₹316 crores, a year ago. The Profit After Tax (PAT) stood at ₹46 crores, down by 21% from the previous year. For the nine-month period ending March 31, 2024, sales was ₹852 crores, vs ₹913 a year ago. The PAT for the nine-month period was ₹184 crores, compared to ₹200 crores a year ago.

**Mr. Milind Thatte, Managing Director, P&G Health India,** said, *“The Company’s continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter’s sales owing to the transition and optimization of trade management and inventory. However, we have seen sales recover in the months of March and April.*

*We continue to drive operational efficiency and explore innovative solutions to accelerate category growth and demand for our portfolio of trusted, quality healthcare brands. The quarter also witnessed prescription growth and share gain for our doctor detailed products indicating a robust demand, and increased efforts to improve awareness of our self-select products.*

*We remain confident in our integrated growth strategy of a focused product portfolio where performance drives brand choice, superiority, productivity, constructive disruption, and an agile and accountable organization structure to help drive growth and value creation,” he added.*

**About Procter & Gamble Health Limited:** Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

**About Procter & Gamble:** P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

### CONTACTS

**Media Contacts - Procter & Gamble Health Limited:**  
Paromita Kundu | [kundu.p.1@pg.com](mailto:kundu.p.1@pg.com)

**Agency Contact - 20:20 MSL:**  
Priyanshi Shah | [priyanshi.shah@2020msl.com](mailto:priyanshi.shah@2020msl.com)  
Bidisha Mohanty | [bidisha.mohanty@2020msl.com](mailto:bidisha.mohanty@2020msl.com)